LENSAR (LNSR) Competitors

RxSight (NASDAQ:RXST) and LENSAR (NASDAQ:LNSR) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, community ranking, media sentiment, profitability, analyst recommendations, risk and valuation.

Do analysts rate RXST or LNSR?

RxSight currently has a consensus price target of $37.90, suggesting a potential upside of 138.51%. LENSAR has a consensus price target of $15.00, suggesting a potential upside of 7.30%. Given RxSight's stronger consensus rating and higher possible upside, equities research analysts clearly believe RxSight is more favorable than LENSAR.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RxSight	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.30
LENSAR	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Which has preferable valuation and earnings, RXST or LNSR?

LENSAR has lower revenue, but higher earnings than RxSight. RxSight is trading at a lower price-to-earnings ratio than LENSAR, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RxSight	$148.31M	4.35	-$48.61M	-$0.67	-23.72
LENSAR	$57.07M	2.89	-$14.38M	-$4.85	-2.88

Is RXST or LNSR more profitable?

RxSight has a net margin of -23.92% compared to LENSAR's net margin of -34.03%. RxSight's return on equity of -14.00% beat LENSAR's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RxSight	-23.92%	-14.00%	-12.51%
LENSAR	-34.03%	-49.02%	-21.12%

Which has more volatility and risk, RXST or LNSR?

RxSight has a beta of 1.32, indicating that its share price is 32% more volatile than the S&P 500. Comparatively, LENSAR has a beta of 0.56, indicating that its share price is 44% less volatile than the S&P 500.

Does the MarketBeat Community favor RXST or LNSR?

RxSight received 46 more outperform votes than LENSAR when rated by MarketBeat users. Likewise, 63.41% of users gave RxSight an outperform vote while only 37.50% of users gave LENSAR an outperform vote.

Company	Underperform	Outperform
RxSight	Outperform Votes 52 63.41%	Underperform Votes 30 36.59%
LENSAR	Outperform Votes 6 37.50%	Underperform Votes 10 62.50%

Do insiders and institutionals believe in RXST or LNSR?

78.8% of RxSight shares are owned by institutional investors. Comparatively, 40.2% of LENSAR shares are owned by institutional investors. 9.4% of RxSight shares are owned by insiders. Comparatively, 38.5% of LENSAR shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Does the media refer more to RXST or LNSR?

In the previous week, RxSight had 16 more articles in the media than LENSAR. MarketBeat recorded 16 mentions for RxSight and 0 mentions for LENSAR. LENSAR's average media sentiment score of 1.67 beat RxSight's score of 1.48 indicating that LENSAR is being referred to more favorably in the news media.

Company	Overall Sentiment
RxSight	Positive
LENSAR	Very Positive

Summary

RxSight beats LENSAR on 14 of the 18 factors compared between the two stocks.